title: Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium.
abstract: OBJECTIVE
  A decision analytic model was built to assess the paediatric rotavirus gastroenteritis (RVGE) burden and potential benefits associated with the introduction of RotaTeq (pentavalent rotavirus vaccine) in Belgium.
  
  
  RESULTS
  In the absence of a rotavirus (RV) immunisation programme, paediatric RVGE was estimated to account for about 5,860 hospitalisations, 1,720 cases of nosocomial infections, 9,410 cases treated by general practitioners/paediatricians (GP/P) and 10,790 cases not seeking medical care for a birth cohort followed up to 5 years of age. Paediatric RVGE was estimated to cost about euro9.0 million from the Belgian healthcare provider perspective and euro15.3 million to society. Given a 90% RV vaccination coverage rate, the pentavalent RV vaccine would have a high impact on RV burden by preventing more than 4,850 hospitalisations, 995 cases of nosocomial infections, 7,145 cases treated by GP/P and 8,190 cases not seeking medical care, and reduce RVGE costs by euro7.1 million from the Belgian healthcare provider perspective and euro12.0 million to society.
authors.affiliation: sanofi pasteur MSD, avenue Jules Bordet 13 Brussels 1140, Belgium.
authors.forename: Patrick
authors.initials: P
authors.lastname: Dhont
authors.forename: Mélanie
authors.initials: M
authors.lastname: Trichard
authors.forename: Nathalie
authors.initials: N
authors.lastname: Largeron
authors.forename: Rachid
authors.initials: R
authors.lastname: Rafia
authors.forename: Stève
authors.initials: S
authors.lastname: Bénard
mesh_terms: D000367:Age Factors; D001530:Belgium / Q000453:epidemiology; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D005759:Gastroenteritis / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D017589:Immunization Programs / Q000191:economics; D007223:Infant; D007231:Infant, Newborn; D018803:Models, Economic; D012400:Rotavirus Infections / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000191:economics*; D012680:Sensitivity and Specificity; D014613:Vaccines, Attenuated / Q000191:economics
chemical_list: C492535:RotaTeq; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated